'''

How My AI Startup Almost Died Before We Pivoted to a $10M Niche in Drug Discovery

We were three months from running out of cash. Three months from joining the long graveyard of failed startups.

We had a brilliant team, a sophisticated AI model for mental health analysis, and the backing of some respectable investors. On paper, we were a success story waiting to happen. But in reality, we were about to hit a wall, and hit it hard. Most founders think building a great AI model is enough. They're wrong. Here's the uncomfortable truth about what it really takes to succeed in the brutal, regulated world of healthcare AI.

The Siren Song of a "Perfect" Model

For the first year, we were obsessed with our model. We spent hundreds of thousands of dollars and countless hours fine-tuning our algorithms, chasing another percentage point of accuracy. We could predict the likelihood of a depressive episode with what we thought was stunning precision. We were technologists in love with our tech.

Our pitch was simple: our AI could help therapists and psychiatrists provide better care. We’d sell to clinics, hospitals, and mental health platforms. The market was huge, the need was obvious. What could go wrong?

Everything.

A World of No

Our first meetings with potential customers were a disaster. We’d walk in, buzzing with excitement, and present our beautiful, complex model. The response? A polite but firm "no."

• "Your model is a black box. Our clinicians need to understand how it works."
• "How does this integrate with our ancient, creaking EMR system?"
• "Who is liable if your AI makes a mistake? Us or you?"
• "Our budget for new technology is zero. Literally zero."

We were naive. We thought a better model was the key. But in healthcare, the technology is only a tiny piece of the puzzle. The real challenges are regulation, integration, and sales cycles that can last for years. We were trying to sell a Ferrari to someone who needed a tractor. And we were running out of time.

The Pivot

One night, over cheap pizza and stale coffee, my co-founder, a computational biologist I’d known since our Stanford days, threw out a crazy idea. "What if we stopped trying to sell to doctors and started selling to drug companies?"

It sounded insane. We were a mental health company. What did we know about drug discovery?

But as he talked, it started to make sense. The same AI that could analyze language patterns for mental health could also analyze scientific papers and clinical trial data. We could use our tech to find new connections, new potential uses for existing drugs, new avenues for research.

It was a long shot. A Hail Mary. But it was better than dying.

We spent the next month locked in a room, tearing our model apart and rebuilding it for this new purpose. We called it "Project Lazarus." We fed it every scrap of public data we could find on a specific class of drugs. And we found something. A small, overlooked connection that suggested a drug for a rare autoimmune disease might have potential for treating a specific type of cancer.

From Zero to $10 Million

We took our findings to a mid-sized pharmaceutical company. We didn’t have a polished product. We had a single, powerful insight. This time, the reaction was different. Their eyes lit up. They weren’t asking about liability or integration. They were asking how fast we could get them more insights.

That single insight led to a $500,000 pilot project. The pilot was a success. Six months later, we signed a multi-year, $10 million contract. We had found our niche. We weren’t a mental health company anymore. We were a drug discovery AI company.

What I Learned From Almost Dying

That near-death experience taught me more than my two successful exits combined. Here are the lessons that are seared into my brain:

• Fall in love with a problem, not a solution. We were so in love with our AI model that we couldn’t see that it was the wrong solution for the problem we were trying to solve.
• The market tells you what it wants. Listen. We spent a year ignoring what the market was telling us. The moment we started listening, we found our path.
• Niches are where the money is. The mental health market was huge and crowded. The drug discovery niche was smaller, but the customers had a burning need and the budget to pay for a solution.
• Sometimes, you have to be willing to kill your darlings. Pivoting was the hardest decision we ever made. It felt like a failure. But it was the only thing that saved us.

Building a startup is a brutal, beautiful, and often counterintuitive journey. You will be wrong more than you are right. You will face rejection and failure. But if you can listen, adapt, and be willing to throw your most cherished ideas in the trash, you just might survive. And in the world of startups, survival is everything. ''')) HBox(children=(FloatProgress(value=0.0, max=1.0), HTML(value=

Frequently Asked Questions

What's the most common pushback you get on this?

People often push back by citing exceptions or edge cases. And they're usually right that exceptions exist. But building a strategy around exceptions rather than patterns is a losing game for most founders.

What experience informs this perspective?

This perspective comes from over a decade of building companies in Silicon Valley, two successful exits (RemoteTeam to Gusto, MovieLaLa to Gfycat), and investing in 200+ startups including Anthropic, OpenAI, and Scale AI. I write about what I've lived.

Do all experts agree with this view?

No, and that's fine. The best ideas in business are often contrarian. I share my perspective based on my experience and data, but I encourage you to seek out opposing viewpoints and form your own conclusions.

How can I apply this thinking to my own situation?

Start by identifying the core principle behind the opinion, not the specific example. Then ask yourself: does this principle apply to my context? If yes, test it in a small, low-risk way before going all in.